To address this perception risk, then-APA President Alan Schatzberg, M.D., working with the new chair of APA's Steering Committee on Practice Guidelines, Joel Yager, M.D., appointed an independent panel to review the guideline before its approval by the APA Board of Trustees. The panel, chaired by Victor Reus, M.D., consisted of experts in depression treatment without current ties to industry. The panel noted that in accordance with available evidence, no particular antidepressant medication is identified by the guideline as more effective or preferred over other antidepressants. In addition, for the treatment of mild and moderate major depressive disorder, the guideline recommends psychotherapy and pharmacotherapy equally. Furthermore, for treatment-resistant depression, newer patented techniques such as transcranial magnetic stimulation and novel pharmacotherapies, including adjunctive second-generation antipsychotics, are described as options supported by accruing evidence. As a result of these observations, the independent panel concluded that the guideline was free of bias, and in March, the Board approved the guideline for publication.